Reducing the cost and increasing the speed of preclinical research in the pharma...
Reducing the cost and increasing the speed of preclinical research in the pharmaceutical industry
Genome Biologics’ novel drug discovery platform addresses the inefficiencies in pre-clinical studies with a unique combination of genomics, molecular science and big data analytics. Using patented single cell transgenic technology...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
GENBIO
Reducing the cost time and ethical burden of preclinical r...
3M€
Cerrado
IPT-2012-0576-090000
DESARROLLO DE MEDICAMENTOS GENÉRICOS PARA EL TRATAMIENTO DE...
696K€
Cerrado
GenDrug
Genetically anchored drug target discovery for neglected dis...
1M€
Cerrado
UNAB13-4E-1659
Sistema de cálculo intensivo y almacenamiento en red de alta...
82K€
Cerrado
SAF2017-88908-R
UNA APROXIMACION DE MEDICINA DE SISTEMAS BASADA EN MODELOS D...
194K€
Cerrado
Información proyecto Genome Biologics
Duración del proyecto: 4 meses
Fecha Inicio: 2017-05-12
Fecha Fin: 2017-09-30
Líder del proyecto
GENOME BIOLOGICS UG
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Genome Biologics’ novel drug discovery platform addresses the inefficiencies in pre-clinical studies with a unique combination of genomics, molecular science and big data analytics. Using patented single cell transgenic technology, the platform can express 50 different genes in a single animal in 6-8 weeks. This breakthrough approach reduces pre-clinical study time and costs by a factor of 10x, allowing pharmaceuticals companies to bring drug candidates to the stage of human trials in 3-6 months instead of 7-10 years. This drastic cost and time reduction will make it economically possible for pharmaceutical companies to bring affordable and effective treatments for rare diseases, as well as (non-orphan) non-communicable diseases, such as cardiovascular diseases, cancers, chronic respiratory diseases and diabetes, which carry an increasing burden for healthcare systems treating an ageing population.
The novel platform also brings a step-change in transgenic animal models: 50-100x less animals are required to generate a reliable model, which reduces drastically the number of animals required in pre-clinical studies and the related ethical burden for pharmaceuticals companies.
The solution uses a patent protected DNA/RNA adeno-associated virus technology that enables testing of up to 50 disease-related genes in a target tissue of interest simultaneously, while at the same time ensuring that each of the cells expresses only a single gene. The technology is addressing a market where pharmaceutical companies currently spend €1Bn per year on animal models. We will interview 40 target customers in phase 1 in order to validate the market potential of the solution, and confirm our initial willingness to pay analysis. We will also identify technical improvement areas and define a go to market plan.